Keros Therapeutics
Keros lead program is focused on inhibition of ALK2, the genetic driver for the orphan disease fibrodysplasia ossificans progressive (FOP), which promotes the transformation of muscle into bone. ALK2 has been validated as a critical node through human genetics and in vivo data.
